Trial Profile
A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Elobixibat (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Albireo AB
- 19 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 19 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.